TransSafeTM Mycoplasma Prevention Reagent
支原體預(yù)防試劑
| 目錄號(hào) | 規(guī)格 | 單價(jià) |
|---|---|---|
| FM501-01 | 1 ml | 290 |
| FM501-02 | 5×1 ml | 1100 |
產(chǎn)品詳情介紹
本產(chǎn)品是對(duì)支原體具有抑制作用的三種抗生素的混合物，分別為大環(huán)內(nèi)酯類(lèi)、氟喹諾酮類(lèi)和四環(huán)素類(lèi)衍生物抗生素，可以有效干擾支原體的蛋白表達(dá)和 DNA復(fù)制。本產(chǎn)品可以有效地預(yù)防細(xì)胞培養(yǎng)過(guò)程中支原體的污染，同時(shí)還能預(yù)防常見(jiàn)的革蘭氏陽(yáng)性菌和陰性菌，日常細(xì)胞培養(yǎng)中替代雙抗使用效果更好，作用濃度低，幾乎沒(méi)有細(xì)胞毒性。
支原體介紹視頻
1.Wang S, Han Q, Qin W, et al. PhenoModel: A multimodal phenotypic drug design foundation model for discovering novel potential inhibitors of multiple cancer cells[J]. Acta Pharmaceutica Sinica B, 2025.(IF 14.80)
2.Zhang Y, Li Y, Zhang Z, et al. CD49a targeting enhances NK cell function and antitumor immunity[J]. Cancer Immunology Research, 2025, (IF 8.20)
3.Gao J, Li C, Wang X, et al. Oridonin attenuates lung inflammation and fibrosis in silicosis via covalent targeting iNOS[J]. Biomedicine & Pharmacotherapy, 2022.(IF 7.50)
4.Ye H, Kang L, Yan X, et al. MiR-103a-3p promotes Zika virus replication by targeting OTU Deubiquitinase 4 to activate p38 mitogen-activated protein kinase signaling pathway[J]. Frontiers in Microbiology, 2022.(IF 6.06)
